Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001320158 | SCV001510933 | pathogenic | not provided | 2024-04-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn217Thrfs*27) in the CTNNA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTNNA1 are known to be pathogenic (PMID: 32051609, 34425242). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CTNNA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1020564). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV003375217 | SCV004096386 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-06-29 | criteria provided, single submitter | clinical testing | The c.648delG variant, located in coding exon 5 of the CTNNA1 gene, results from a deletion of one nucleotide at nucleotide position 648, causing a translational frameshift with a predicted alternate stop codon (p.N217Tfs*27). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. The evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear. |